Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) and a major contributor to disability of young adults in western countries. MS prevalence is highest in areas with low vitamin D. Vitamin D is a fat-soluble compound with numerous physiologic responses, including immune regulation. An increasing volume of work suggests that lower levels of serum vitamin D are associated with an increased risk of MS and a more severe disease course. With the suggestion of a role in MS disease activity, increasing attention is being paid to the potential of using vitamin D as an add-on therapy to established MS disease-modifying therapies. Several preliminary studies have reported results which have shown some promise, but none has yet provided significant evidence of a clinically meaningful improvement. We review our recommendations for off-label supplementation in the context of these findings.
McAlpineD.Multiple sclerosis: A review. Br Med J1973; 2(5861): 292–295.
2.
DuttaRTrappBD.Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol2011; 93(1): 20946934.
3.
WallinMTPageWFKurtzkeJF.Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Ann Neurol2004; 55(1): 65–71.
4.
HaganKAMungerKLAscherioAet al. Epidemiology of major neurodegenerative diseases in women: Contribution of the nurses’ health study. Am J Public Health2016; 106(9): 1650–1655.
5.
MungerKLKöchertKSimonKCet al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Transl Neurol2014; 1(8): 605–617.
6.
JurutkaPWWhitfieldGKHsiehJCet al. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord2001; 2(2): 203–216.
7.
DeLucaHF.The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J1988; 2: 224–236.
MungerKLLevinLIHollisBWet al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006; 296(23): 2832–2838.
10.
RheadBBäärnhielmMGianfrancescoMet al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet2016; 2(5): e97.
11.
MokryLERossSAhmadOSet al. Vitamin D and risk of multiple sclerosis: A Mendelian randomization study. PLoS Med2015; 12(8): e1001866.
12.
GianfrancescoMAStridhPRheadBet al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology2017; 88(17): 1623–1629.
13.
EbersGC.Environmental factors and multiple sclerosis. Lancet Neurol2008; 7(3): 268–277.
14.
LincolnMRMontpetitACaderMZet al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet2005; 37(10): 1108–1112.
15.
RamagopalanSVMaugeriNJHandunnetthiLet al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet2009; 5(2): e1000369.
16.
RamagopalanSVDymentDACaderMZet al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol2011; 70(6): 881–886.
17.
BermelRAYouXFouldsPet al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol2013; 73(1): 95–103.
18.
RudickRALeeJ-CSimonJet al. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol2006; 60(2): 236–242.
19.
Løken-AmsrudKIHolmøyTBakkeSJet al. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology2012; 79(3): 267–273.
20.
MowryEMWaubantEMcCullochCEet al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol2012; 72(2): 234–240.
21.
FitzgeraldKCMungerKLKöchertKet al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol2015; 72(12): 1458–1465.
22.
MowryEMPelletierDGaoZet al. Vitamin D in clinically isolated syndrome: Evidence for possible neuroprotection. Eur J Neurol2016; 23(2): 327–332.
23.
SimpsonSTaylorBBlizzardLet al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol2010; 68(2): 193–203.
24.
MowryEMKruppLBMilazzoMet al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol2010; 67(5): 618–624.
25.
SmoldersJMenheerePKesselsAet al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler2008; 14(9): 1220–1224.
26.
ZhangYLiuGHanXet al. The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China. J Neuroimmunol2016; 297: 127–131.
27.
GoldbergPFlemingMCPicardEH.Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses1986; 21(2): 193–200.
28.
KampmanMTSteffensenLHMellgrenSIet al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial. Mult Scler2012; 18(8): 1144–1151.
29.
SteinMSLiuYGrayOMet al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011; 77(17): 1611–1618.
30.
KimballSMUrsellMRO’ConnorPet al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr2007; 86(3): 645–651.
31.
Soilu-HänninenMÅivoJLindströmBMet al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry2012; 83(5): 565–571.
32.
BurtonJMKimballSViethRet al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010; 74(23): 1852–1859.
33.
SmoldersJHuppertsRMMViethRet al. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon ß-1a (scIFNß-1a). ECTRIMS Online Library; Sep16, 2016; 147013.
34.
CamuW.Cholecalciferol supplementation in relapsing multiple sclerosis patients treated with subcutaneous interferon beta-1a: A randomized controlled trial. Neurology2017; 88(Suppl. 16): S44.004.
35.
RossACTaylorCLYaktineALet al. (eds). Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press, 2011.
36.
HiremathGCettomaiDBaynesMet al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler2009; 15(6): 735–740.
37.
BhargavaPSteeleSUWaubantEet al. Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler2016; 22(6): 753–760.
